Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

PharmaForce International: Research Indicates Continued Migration Toward Specialty Oncology Sales Forces and Novel Breakthrough Medical Therapy Options for Cancer Patients

PharmaForce International
Posted on: 13 Feb 18
PharmaForce International: Research Indicates Continued Migration Toward Specialty Oncology Sales Forces and Novel Breakthrough Medical Therapy Options for Cancer Patients New classes of therapy-including CAR-T as well as recent approvals for a variety of solid and liquid tumor drugs-require innovative "go-to-market" strategies for companies competing in this dynamic therapeutic area.

PR Newswire

READING, Pa., Feb. 13, 2018

READING, Pa., Feb. 13, 2018 /PRNewswire/ -- Research published by PharmaForce International (PFI) shows 31% of pharmaceutical and biotech companies are deploying multiple oncology sales force sleeves that support an individual product. This strategic approach is employed in an effort to capitalize on opportunities to increase sales across indications for the same medication.

These findings, along with more granular data are contained in PFI's Oncology benchmarking study. This well-respected and widely referenced report is in its 17th annual edition and examines a cross-section of over 35 companies in the oncology therapeutic area.

Joyce Wedemeyer, Director of Marketing and Sales at PharmaForce International, notes that many recently approved oncology medications have been granted multiple indications by the FDA.

"A wave of immuno-oncology drugs have been approved by the FDA in the past few years. At the same time, opportunities to improve patient outcomes are presenting themselves by pairing these new medications with others already available to the oncologist."

"In many instances, companies market these new indications as being patient-specific, and a specialized sales approach is necessary to drive product uptake across tumor types," Wedemeyer said. 

"Combination and targeted therapies are accelerating trends in the oncology space," she continued. "We envision a day in the not-too-distant future where many types of cancers may be managed over time as chronic diseases."

Additional industry trends captured in the report include insights specific to:

  • Specialized HEOR approaches
  • Expanded roles for Key Account Managers
  • Recently deployed field-based Marketing Managers
  • Adoption of diagnostic genetic testing personnel
  • Emerging biosimilar competitors
  • Newly deployed Thought Leader Teams to engage Key Opinion Leaders

For more information on the report mentioned above, please contact Joyce Wedemeyer at  Joyce.Wedemeyer@strategicreports.com   or by phone at 610-370-2906.

PharmaForce International  (PFI) is a competitive intelligence firm with over two decades of experience in the pharmaceutical and biotech industries. PFI has become the market leader in commercial operations benchmarking and competitive intelligence. The globally focused company employs marketplace experts uniquely qualified to perform research required by clients in most major pharmaceutical markets around the world, including Europe, India, Japan, Latin America, and the United States.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/pharmaforce-international-research-indicates-continued-migration-toward-specialty-oncology-sales-forces-and-novel-breakthrough-medical-therapy-options-for-cancer-patients-300596073.html

SOURCE PharmaForce International

PR Newswire
www.prnewswire.com

Last updated on: 13/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.